US › Healthcare

Anixa Biosciences Inc (ANIX)

US · Healthcare · Biotechnology

$3.410.00%
Last close · 2026-08-04

Latest quarter · ended 2026-04-30

Revenue
$0
Net profit
$-2.6M
Profit YoY
+8.4%
EPS
$-0.07
EPS estimate
$-0.10

EPS came in at -0.07 against a street estimate of -0.10 — a beat of 30.0%.

Key statistics

Market cap
$116.4M
Forward P/E
0.0
P/B
8.03
Book value
$0.43
EPS (TTM)
$-0.30
52-week high
$5.46
52-week low
$2.32
50-day MA
$2.96
200-day MA
$3.27
Beta
0.60

Analyst view

Analysts rate Anixa Biosciences Inc a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $10.00.

Shareholding

Insiders
5.48%
Institutions
13.40%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.87%
Laird Norton Tyee Trust Co1.66%
UBS Group AG1.62%
Davidson D A & Co1.58%
Geode Capital Management, LLC1.07%
Vanguard Fiduciary Trust Co0.56%
Marshall Wace Asset Management Ltd0.51%
BlackRock Inc0.50%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Anixa Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.